Senior Operational Strategy Director

McKesson signs agreement to acquire Precision Medicine Group, LLC. Key Takeaway: McKesson Corporation has signed a definitive agreement to acquire Precision Medicine Group for approximately $2.25 billion. This acquisition aims to enhance McKesson's offerings in clinical research and biopharma commercialization. Post-transaction, Precision Medicine Group will be integrated into McKesson's Oncology & Multispecialty segment. Market sentiment analysis. Positive factors. * McKesson is expanding its capabilities in clinical research. * The acquisition enhances McKesson's oncology and multispecialty services. * Precision Medicine Group is a reputable provider in biopharma commercialization. BiopharmaWatch analysis. From its catalyst data and publicly available data · not financial advice Cash runway Minimal dilution risk Lead asset Pegylated liposomal doxorubicin Phase 2 · Metastatic Breast Cancer IRVING, Texas-(BUSINESS WIRE)-McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC ("Precision Medicine Group"), a global provider of clinical research and biopharma commercialization services. McKesson will acquire Precision Medicine Group for approximately $2.25 billion. Following completion of the transaction, Precision Medicine Group will report within McKesson's Oncology & Multispecialty segment. The transacti Frequently asked questions. What is the value of McKesson's acquisition? McKesson's acquisition of Precision Medicine Group is valued at approximately $2.25 billion. What services does Precision Medicine Group provide? Precision Medicine Group is a global provider of clinical research and biopharma commercialization services. In which segment will Precision Medicine Group report? After the acquisition, Precision Medicine Group will report within McKesson's Oncology & Multispecialty segment.

Telix posts strong quarter as revenue nears billion dollar annual run rate. Telix Pharmaceuticals (ASX:TLX) has reported robust commercial momentum in the quarter ended June 30, 2026, with group revenue of US$247 million, up 21 per cent year over year and 7 per cent from the prior quarter. Precision Medicine led growth with US$202 million in revenue, a 30 per cent increase year over year and 9 per cent sequentially, while Telix Manufacturing Solutions contributed US$45 million. The company said revenue is tracking toward the upper end of its financial year 2026 guidance. It expects revenue and other income to exceed US$1 billion, including a US$40 million non-refundable payment from Regeneron. The company said the quarter featured several regulatory and clinical advances across both the Therapeutics and Precision Medicine portfolios. The United States Food and Drug Administration provided alignment that allows the ProstACT global Phase 3 study of TLX591 Tx to advance to Part 2 in the U.S. Enrollment is progressing in multiple regions, and the program has regulatory approval to commence in China. The OPTIMAL PSMA program completed enrollment in its OPTIMAL PSMA study and has begun dosing in the OPTIMAL-e Phase 2 study for earlier-stage disease. Telix also dosed the first patient in LUTEON, a pivotal trial of TLX250 Tx in clear cell renal cell carcinoma, and enrolled initial cohorts in IPAX BrIGHT, a pivotal trial of TLX101 Tx in recurrent glioblastoma. On the imaging side, Telix reported rapid BiPASS enrollment for Illuccix and Gozellix, and completed patient enrollment in Japan for the registrational study of TLX591 Px with a New Drug Application in preparation. The company said the FDA accepted the resubmitted NDA for Pixclara and granted a PDUFA goal date of September 11, 2026. Telix is also advancing its BLA resubmission for Zircaix and nearing completion of final CMC documentation. Commercial and operational expansion continued with new manufacturing capacity and supply chain investments. Telix recently opened a Telix Manufacturing Solutions (TMS) facility in North Melbourne in partnership with the Melbourne Theranostic Innovation Centre and completed a first GMP production run at TMS Brussels South. The company installed an ARTMS QUANTM irradiation system at TMS Yokohama as part of its plan to scale isotope production globally. Corporate developments during the quarter included a strategic collaboration with Regeneron to jointly develop next-generation radiopharmaceutical therapies and the receipt of an initial US$40 million non-refundable payment. Telix also completed a refinancing by issuing US$600 million of convertible bonds due 2031 and repurchasing its 2029 bonds. Three new non-executive directors joined the board as part of succession planning. Managing Director and Group CEO Dr Christian Behrenbruch said, "We delivered another quarter of growth with U.S. dose volumes increasing 7% during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA imaging portfolio. This performance underscores the strength of our differentiated two-product PSMA imaging strategy and reinforces Telix's market leadership, built on clinical differentiation, supply chain resilience and commercial execution. During the quarter, we achieved key regulatory, commercial and clinical milestones across both our Precision Medicine and Therapeutics businesses. We are tracking in line with the upper end of our FY 2026 revenue guidance and are investing further in R&D to accelerate a number of high-value programs that have the potential to create significant future growth and shareholder value."

Lir Life Sciences Corp. formerly Blackbird Critical Metals Corp. announces closing of acquisition of Lir Life Sciences Inc. VANCOUVER, BC / ACCESS Newswire / November 10, 2025 / Lir Life Sciences Corp. (CSE:SKNY) (formerly Blackbird Critical Metals Corp.) ("Lir Life Sciences" or the "Company") is pleased to announce, further to its news release dated August 14, 2025, that it has completed the acquisition (the "Transaction") of all of the issued and outstanding shares of Lir Life Sciences Inc. ("Lir Inc."), and that trading in the common shares of the Company resumed on the Canadian Securities Exchange (the "CSE") on November 7, 2025, under the ticker symbol "SKNY". The Company acquired 100% of the issued and outstanding shares of Lir Inc. in consideration for the issuance of 22,312,678 post-consolidated common shares of the Company to the former securityholders of Lir Inc. In connection with the completion of the Acquisition, the Company also issued 379,000 common shares (the "Admin Fee Shares") to The Back Office Inc., an arm's-length third party, as an administrative fee for services rendered in support of the Acquisition. The Admin Fee Shares are subject to a statutory hold period of four months and one day under applicable Canadian securities laws. The Company is pleased to announce that Dr. Edward Mills has been appointed Chief Executive Officer and as a Director of the Company. Dr. Mills is a globally recognized leader in clinical trials and public health, with over 550 peer reviewed publications in top-tier journals such as The New England Journal of Medicine and The Lancet. Over the past two decades, he has led some of the largest and most impactful clinical trials ever conducted, particularly focused on evaluating treatments for diseases affecting low-income populations. His work has earned him multiple prestigious awards in clinical research. Dr. Mills has raised over $1 billion to support clinical research and public health initiatives and is among the most widely published clinical researchers in the world. He holds a PhD in clinical research and two master's degrees. Formerly Chief Executive Officer of Platform Life Sciences and a Senior Scientist at VirX@Stanford, he continues to pioneer breakthrough therapies. He is also a successful entrepreneur, having co-founded and exited several healthcare companies, including MTEK Sciences (acquired by Cytel) and Redwood Outcomes (acquired by Precision Medicine Group). Dr. Mills will lead the Company's vision around the development of therapies intended to provide accessible obesity treatment through transdermal delivery. The Company also welcomes Mr. Harry Nijjar as Chief Financial Officer and Corporate Secretary. Mr. Nijjar is the Managing Director at Malaspina Consultants and a seasoned finance executive with extensive experience in financial reporting, corporate governance, and strategic advisory across a wide range of industries. He serves as Chief Financial Officer for multiple public companies and has held Chief Financial Officer positions with numerous TSX Venture Exchange and CSE listed issuers. Mr. Nijjar earned a Bachelor of Commerce from the Sauder School of Business at the University of British Columbia in 2010 and obtained his CPA, CMA designation in 2012. The Company also welcomes Dr. Mark Dybul as a Director. Dr. Dybul is a Professor in the Department of Medicine at Georgetown University Medical Center where he serves as Chief Strategy Officer of the Center for Global Health Practice and Impact. He is also Chair of the Board of Purpose Africa. Dr. Dybul has worked on HIV and public health for more than 25 years as a clinician, scientist, teacher, and administrator. He was a principal architect of and ultimately led with the rank of Ambassador at the level of an Assistant Secretary of State, the US President's Emergency Plan for AIDS Relief ("PEPFAR"). More recently, he served as the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. The Company also welcomes Mr. Kevin May as a Director. Mr. May is an experienced lumber trader with a deep understanding of the North American lumber market, supply chain dynamics, and sustainable forestry practices. With a keen ability to navigate complex trade relationships, he plays a pivotal role in sourcing and distributing high quality timber products to meet the needs of diverse industries. Before transitioning into the lumber trade, Mr. May built a strong foundation in international relations as a cross-cultural communicator in Japan. This experience honed his skills in negotiation, market analysis, and relationship management, the essential qualities that now drive his success in the highly competitive lumber industry. In connection with the Acquisition, and as disclosed by way of news release on October 29, 2025, Lir Inc. completed a non-brokered private placement of 3,050,270 subscription receipts at a price of $0.35 per subscription receipt (the "Concurrent Financing"), for aggregate gross proceeds of $1,067,594.50. Each subscription receipt automatically converted into one common share of Lir Inc. immediately prior to Closing, and such Lir Inc. shares were exchanged for common shares of the Company on closing. Lir Inc. also settled $109,343 of outstanding debt by issuing 312,408 Lir Inc. shares at a deemed price of $0.35 per Lir Inc. share, (the "Debt Conversion") which were exchanged for common shares of the Company on closing. The securities issued in connection with the Concurrent Financing and Debt Conversion are subject to a voluntary hold period of four months from the date from closing. Prior to Closing, on October 31, 2025, the Company effected a change of its corporate name from "Blackbird Critical Metals Corp." to "Lir Life Sciences Corp." (the "Name Change"). For further information regarding the Acquisition, the Concurrent Financing or the Name Change, please see the Listing Statement of the Company dated November 3, 2025, a copy of which is available under the Company's issuer profile on SEDAR+ at www.sedarplus.ca or on the CSE's website. Lir Life Sciences is focused on researching and developing scalable and affordable treatments for obesity using novel drug delivery methods. The company is advancing a transdermal patch and other novel delivery systems that mimic GLP-1, a naturally occurring hormone that helps regulate appetite and blood sugar. These therapies could potentially offer an alternative to injectable drugs. The goal is to improve access, adherence, and cost-efficiency in both developed and emerging markets. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science. Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains statements and information that, to the extent that they are not historical fact, may constitute "forward-looking information" within the meaning of applicable securities legislation based on current expectations, estimates, forecasts, projections, beliefs and assumptions made by management of the Company. Forward-looking information is generally identified by words such as "believe", "project", "aim", "expect", "anticipate", "estimate", "intend", "strategy", "future", "opportunity", "plan", "may", "should", "will", "would", and similar expressions and, in this news release, includes statements relating to the commencement of trading of the common shares of the Company, the financial and business prospects of the Company, its assets and other matters. Although the Company believes that the expectations and assumptions on which such forward- looking information are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that it will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking information in this news release. The forward-looking information included in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release is made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless so required by applicable laws.